

DRAGON PHARMACEUTICAL INC  
Form 8-K/A  
October 23, 2009  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**Amendment No. 1**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 9, 2009

**DRAGON PHARMACEUTICAL INC.**

(Exact name of registrant as specified in its charter)

**Florida**

(State or Other Jurisdiction of  
Incorporation)

**000-27937**

(Commission File Number)

**65-0142474**

(IRS Employer  
Identification No.)

**650 West Georgia Street, Suite 310**

**Vancouver, British Columbia**

(Address of Principal Executive Offices)

**V6B 4N9**

(Zip Code)

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K/A

(604) 669-8817

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

---

**Section 4 - Matters Related to Accountants and Financial Statements**

**Item 4.01 Changes in Registrant's Certifying Accountant.**

**(a) Previous Independent Accountants**

On October 9, 2009, Dragon Pharmaceutical Inc. decided not to reappoint Ernst & Young LLP ("E&Y") as our independent accountant for the year ending December 31, 2009.

We provided our former independent accountant, E&Y, with a copy of the disclosures expressed in our Form 8-K filed on October 14, 2009, and incorporated herein by reference, and we requested that E&Y furnish us with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with such statements. We are amending the prior Form 8-K to include a copy of E&Y's letter, which is attached hereto as Exhibit 16.

**Section 9 – Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits**

<u>Exhibit No.</u>	<u>Exhibit Description</u>
16	Letter from Ernst & Young LLP

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DRAGON PHARMACEUTICAL INC.,**  
a Florida Corporation

Dated: October 22, 2009  
/s/ Maggie Deng

Maggie Deng

Chief Operating Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
16	Letter from Ernst & Young LLP